Abstract: The present disclosure provides COL5A2-ALK fusion nucleic acid molecules and polypeptides, and COL3A1-ALK fusion nucleic acid molecules and polypeptides, as well as methods, kits and reagents for detecting such fusion nucleic acid molecules and polypeptides. The disclosure also provides methods for evaluating, identifying, assessing, and/or treating an individual having a cancer.

Abstract: Provided herein are methods related to detecting overexpression of an oncogene through translocations in the immunoglobulin heavy (IGH) locus, as well as methods of treatment, uses, and kits related thereto. As demonstrated herein, IGH translocations lead to oncogene overexpression when the distance from a breakpoint of the translocation to the transcription start site (TSS) of an oncogene is within 0-1.3 Mb. As such, detecting IGH translocations in which a breakpoint is 1.3 Mb or less from an oncogene TSS may find use, e.g., in detecting oncogene overexpression, providing assessment/diagnosis, identifying individuals for treatment, selecting therapies, identifying treatment options, and treating or delaying progression of cancer, e.g., using relevant targeted and/or non-targeted therapies.

Abstract: NTRK fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing, and/or treating a subject having a cancer are disclosed.